Al­lo­gene Over­land Bio­pharm com­pletes Shang­hai fa­cil­i­ty to man­u­fac­ture CAR-T prod­ucts

Last month, as cell ther­a­py play­er Al­lo­gene launched a study for its can­di­date tar­get­ing large B-cell lym­phoma, its joint ven­ture, Al­lo­gene Over­land Bio­pharm put the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER